UPDATE: Morgan Stanley Reiterates on Pfizer Following Investor Relations Lunch

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer (NYSE: PFE ), but removed the $33.00 price target. In the report, Morgan Stanley noted, “We hosted Chuck Triano and Ryan Crowe from Pfizer Investor Relations for lunch in NYC on Thurs. Dec. 12.